Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BDTX

STRONG SELL

Black Diamond Therapeutics, Inc. · Healthcare · United States · $101M · Avg Vol: $3M/d

16
StockRank
Get insider-trade alerts
Q
45
V
32
M
21
P/E (TTM)
—
ROE
-35.2%
D/E
0.2x
Dividend %
—
Dir. Trades · 180d
None →
Buybacks · 180d
None →

COMPANY DESCRIPTION

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing precision medicines for cancer patients with genetically defined mutations. The company utilizes its proprietary Mutation-Allostery-Pharmacology (MAP) platform to discover and develop novel allosteric and mutation-specific therapies for historically undruggable cancer targets. Black Diamond is a niche biotechnology firm focused on addressing high unmet medical needs in precision oncology.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue000070.0M——5.6M—-92.1%
EPS-3.47-2.52-1.88-1.270.39—-0.78-0.63-1.16—
Shares36.2M36.4M51.6M56.6M57.1M+57.7%57.3M———
Debt28.5M28.1M25.3M22.2M18.8M-9.9%17.9M———
Equity195.9M115.7M116.7M83.3M112.2M-13.0%————
Op CF-100.1M-85.1M-66.7M-62.3M29.6M—-34.0M———
Inv CF130.6M53.4M16.3M17.0M-44.9M—————
Fin CF0.7M0.2M71.9M25.5M-0.1M—————
Loading 1Y...
PRICE (1Y)-1.1%
1.611.731.841.962.08Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$1.73
RSI (14)
20.3
52W High
$4.94
From 52W High
0.4%

SCORE BREAKDOWN

Quality
45
ROIC
15.6%86.5
ROE
-35.2%24.2
GP/Assets
0.0%10.1
Op. Margin
0.0%41.3
FCF/Assets
-18.1%20.6
Piotroski
789.5
Int. Cover
—N/A
D/E Ratio
0.17x53.7
Current Ratio
8.46x83.4
Value
32
P/E (TTM)
—N/A
EV/EBITDA
-0.1x25.0
P/FCF
—N/A
P/B
1.0x84.8
P/S
—0.3
Div Yield
—N/A
Momentum
21
52W High %
35%11.5
RS 6M
-42%20.4
SMA 50/200
0.76x13.5
EPS Rev 4W
0.0%62.6
EPS Rev 12W
-12.6%11.7
EPS Improve
-49%9.5
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$101M
P/E (Forward)
-1.6x
Gross Margin
0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BDTX are excluded.

TickerCompanyMkt CapStockRankSignal
BDTXBlack Diamond Therapeutics, Inc.(you)$101M16STRONG SELL
COYACoya Therapeutics, Inc.$100M13STRONG SELL
VRCAVerrica Pharmaceuticals Inc.$86M16STRONG SELL
ANIXAnixa Biosciences, Inc.$126M16STRONG SELL
VANIVivani Medical, Inc.$110M11STRONG SELL
CDXSCodexis, Inc.$135M14STRONG SELL
OSTXOS Therapies Incorporated$68M16STRONG SELL
BMEABiomea Fusion, Inc.$90M10STRONG SELL
CNTBConnect Biopharma Holdings Limited$135M13STRONG SELL
CNTNCanton Strategic Holdings, Inc.$150M15STRONG SELL

Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%

Black Diamond Therapeutics, Inc. (BDTX) — Stock Score Summary

Black Diamond Therapeutics, Inc. (BDTX) has a MoatMap StockRank of 16/100 based on Quality (45/100), Value (32/100), and Momentum (21/100) factor scores. The current signal is STRONG SELL.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing precision medicines for cancer patients with genetically defined mutations. The company utilizes its proprietary Mutation-Allostery-Pharmacology (MAP) platform to discover and develop novel allosteric and mutation-specific therapies for historically undruggable cancer targets. Black Diamond is a niche biotechnology firm focused on addressing high unmet medical needs in precision oncology.

Key Financial Metrics

Price$1.73
Market Cap$101M
P/E (Forward)-1.56
Price/Book0.99
Return on Equity-35.2%
Return on Invested Capital15.6%
Debt/Equity0.17x
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-26M

Black Diamond Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Black Diamond Therapeutics, Inc.’s (BDTX) StockRank?
MoatMap’s StockRank for Black Diamond Therapeutics, Inc. (BDTX) is 16/100, with a Strong Sell signal. It is a composite of Quality (45), Value (32), and Momentum (21) factor ranks across MoatMap’s 20,000+ stock universe.
Does Black Diamond Therapeutics, Inc. have an economic moat?
Black Diamond Therapeutics, Inc. (BDTX) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Black Diamond Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Black Diamond Therapeutics, Inc. (BDTX) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Black Diamond Therapeutics, Inc. in?
Black Diamond Therapeutics, Inc. (BDTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksBDTX deep dive reportAI ChampionsHow we score stocksSense-check another stock